0.05),治療后研究組均低于"/>
王莎莎 張冰 馮文玉
【摘要】 目的:分析急性百草枯中毒(APP)患者采取參附注射液聯(lián)合持續(xù)血液灌流治療效果及其對(duì)肺損傷的影響。方法:選取2018年1月-2019年1月筆者所在醫(yī)院接收的78例急性百草枯中毒患者,根據(jù)先后入院時(shí)間分為兩組,對(duì)照組(n=39)開(kāi)展常規(guī)藥物治療與持續(xù)血液灌流,研究組(n=39)則接受持續(xù)血液灌流聯(lián)合參附注射液,統(tǒng)計(jì)各組治療前后臨床指標(biāo)及肺纖維化發(fā)生率。結(jié)果:治療前兩組血一氧化氮、Ⅲ型前膠原肽、誘導(dǎo)型一氧化氮合酶比較差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05),治療后研究組均低于對(duì)照組,差異均有統(tǒng)計(jì)學(xué)意義(P<0.05);研究組肺纖維化發(fā)生率及治療總有效率分別為20.51%、94.87%,均優(yōu)于對(duì)照組的51.28%、76.92%,差異均有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論:急性百草枯中毒治療過(guò)程中,通過(guò)參附注射液聯(lián)合持續(xù)血液灌流不僅可以改善患者肺損傷,同時(shí)有助于肺纖維化發(fā)生率降低,確保良好的治療效果,值得采納并推廣。
【關(guān)鍵詞】 百草枯 中毒 肺損傷 持續(xù)血液灌流 參附注射液 影響
[Abstract] Objective: To analyze the effect of Shenfu Injection combined with continuous hemoperfusion on patients with acute paraquat poisoning (APP) and its effect on lung injury. Method: From January 2018 to January 2019, 78 patients with acute paraquat poisoning in our hospital were selected, according to the time of admission, they were divided into two groups. The control group (n=39) was treated with the routine drug treatment and continuous blood perfusion, the research group (n=39) was treated with continued blood perfusion combined with Shenfu Injection. The incidence of clinical and pulmonary fibrosis before and after treatment were counted. Result: There were no statistically significant differences in nitric oxide, type Ⅲ procollagen peptide and inducible nitric oxide synthase of two groups before treatment (P>0.05). After treatment, the indexes in the study group were lower than those in the control group, the differences were statistically significant (P<0.05). The incidence of pulmonary fibrosis in the study group and the total effective rate of treatment were 20.51% and 94.87% respectively, better than 51.28% and 76.92% of the control group, the differences were statistically significant (P<0.05). Conclusion: In the course of treatment of acute paraquat poisoning, Shenfu Injection combined with continuous hemoperfusion can not only improve the lung injury, but also help to reduce the incidence of pulmonary fibrosis and ensure good therapeutic effect, which is worth adopting and popularizing.
急性百草枯中毒是我國(guó)常見(jiàn)、多發(fā)農(nóng)藥中毒急危重癥之一,近些年來(lái),臨床上百草枯中毒口服患者越來(lái)越多,而且有上升趨勢(shì)[1]?,F(xiàn)階段,急性百草枯中毒并沒(méi)有特效治療藥物,患者如果未得到及時(shí)治療,具有較高病死率[2]。目前,臨床上主要采取早期血液灌流方式進(jìn)行治療,而且該方法被廣泛應(yīng)用于臨床上。據(jù)有關(guān)資料顯示,中藥參附注射液在氧自由基方面具有拮抗效果,有助于肺循環(huán)改善,而且能夠避免對(duì)肺功能造成嚴(yán)重?fù)p傷[3]?;诖?,本次試驗(yàn)針對(duì)筆者所在醫(yī)院2018年1月-2019年1月接收的急性百草枯中毒患者實(shí)施持續(xù)血液灌流聯(lián)合參附注射液治療效果及其對(duì)肺功能的影響進(jìn)行簡(jiǎn)單分析,以下為詳細(xì)報(bào)告。
1 資料與方法
1.1 一般資料
本次試驗(yàn)78例急性百草枯中毒患者均為筆者所在醫(yī)院2018年1月-2019年1月接收。納入標(biāo)準(zhǔn):(1)與《職業(yè)性急性百草枯中毒的診斷(GBZ246-2013)》中急性百草枯中毒診斷標(biāo)準(zhǔn)相符[4];(2)百草枯(PQ)質(zhì)量濃度在10~30 mg/L;(3)具備完整臨床資料;(4)具備正常溝通及理解能力。排除標(biāo)準(zhǔn):(1)合并精神異常、心理障礙;(2)存在心臟、肝臟及腎臟器官功能不全;(3)存在腦血管疾病、感染性疾病、肺疾病、膿毒癥及其他代謝性疾病;(4)存在藥物過(guò)敏史;(5)由于個(gè)人因素拒絕或者中途選擇退出;(6)存在凝血功能障礙。以先后入院時(shí)間為依據(jù)平均分為兩組,對(duì)照組39例,男20例,女19例;年齡24~51歲,平均(39.56±3.54)歲;平均動(dòng)脈壓(85.62±2.42)mm Hg;血中PQ(3.39±0.37)mg/L;研究組39例,男22例,女17例;年齡25~48歲,平均(39.47±3.48)歲;平均動(dòng)脈壓(86.12±2.37)mm Hg;血中PQ(3.42±3.51)mg/L。兩組一般資料比較差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05)。患者本人或者家屬簽署研究同意書(shū),研究經(jīng)醫(yī)院倫理委員會(huì)批準(zhǔn)。